ProKidney jumps on positive mid-stage data for kidney disease drug
View all comments(0)
Shares of ProKidney PROK.O rise 62.4% to $1.25 cents premarket
Co says its drug, rilparencel, showed improvement in kidney function decline in patients with chronic kidney disease and diabetes during mid-stage trial
PROK has upcoming meeting with Food and Drug Administration to confirm approach of drug's planned late-stage trial
Up to last close, stock down 64% YTD
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Like
Recommended Articles
Featured Tools
Top News
Why SanDisk Stock Could Soar to $4,000?

Is Micron the Next Nvidia? Why the 2026 "Memory Crunch" Makes MU Stock a Top AI Buy

AI Chip Sector Adds Heavyweight Player, Nvidia Rival Cerebras Plans to List Next Week, Targeting Largest US IPO of the Year

'Big Short' Burry Doubles Down: Nvidia, Palantir Short Positions Double in Big Bet on AI Bubble Bursting

Global First Storage ETF Surges 88% Five Weeks After Listing. Is It Too Late to Buy Now?

Tradingkey







Comments (0)
Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.